Can Hashimoto's Thyroiditis Cause Thyroid Nodules?
Yes, Hashimoto's thyroiditis is associated with thyroid nodule development, with nodules occurring in approximately 18-36% of patients with HT, though the relationship appears to be an association rather than direct causation. 1, 2, 3, 4
Prevalence and Risk
Thyroid nodules are common in HT patients, with detection rates ranging from 18.8% to 36.9% across multiple studies, typically appearing after puberty onset in pediatric populations 1, 2, 3
The nodule frequency is similar between overt hypothyroid and euthyroid HT patients (35.5% vs 36.9%), suggesting thyroid function status doesn't significantly influence nodule development 4
Family history of thyroid disease increases risk, with a hazard ratio of 2.1 for nodule detection in HT patients 1
Higher TPOAb titers and severity of hypoechogenicity on ultrasound predict new nodule appearance in HT patients 2
Malignancy Risk Considerations
The presence of HT does not increase the malignancy risk within individual nodules, but the overall cancer detection rate among HT patients with nodules ranges from 4.2% to 7.9% 1, 3, 5
Among detected nodules in HT patients, 22.5-35% may be malignant, which is higher than the general pediatric nodule population 1, 3
HT may actually be a protective factor against PTC progression and metastasis, with lower lymph node metastasis rates (26.0% vs 32.3%) and higher proportions of PTMC when cancer coexists with HT 6
The risk of malignancy in Bethesda Category III nodules is not influenced by HT presence (HT: 5.0-17.5% vs non-HT: 4.7-15.1%) 5
Diagnostic Challenges and Pitfalls
HT creates specific ultrasonographic challenges that can complicate nodule assessment:
Focal nodular HT can mimic malignancy, but typically lacks marked hypoechogenicity, irregular margins, and microcalcifications compared to true malignant nodules 7
In HT patients, 33.1% may have fine calcifications and 45.9% have TI-RADS classification >Level 3, potentially leading to overdiagnosis 6
Focal HT nodules are characteristically purely solid (92.8%), iso-hyperechoic (70.4%), with regular margins (75.0%) and central vascularity (85.7%) 7
Management Approach
Apply standard EU-TIRADS or ACR-TI-RADS criteria for FNAB decisions in HT patients, with the same size thresholds as non-HT patients:
- EU-TIRADS 5 nodules >10mm require FNAB 8
- EU-TIRADS 4 nodules >15mm require FNAB 8
- EU-TIRADS 3 nodules >20mm require FNAB 8
For mixed nodules in HT patients, assess the solid component separately using EU-TIRADS scoring, ensuring the tissue portion is accessible and >10mm 8
In patients with multiple nodules and HT, prioritize FNAB based on individual nodule risk scores rather than assuming all nodules are benign inflammatory changes 8
Consider that overweight/obese HT patients (BMI >24 kg/m²) with PTC may have increased progression risk (HR 6.32), warranting closer surveillance 9